

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 14A

**Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.)**

Filed by the Registrant
Check the appropriate box:

Filed by a Party other than the Registrant

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to §240.14a-12

Novus Therapeutics, Inc.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials:

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount previously paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:



Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to be held on May 12, 2020 for Novus Therapeutics, Inc.

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. To view the proxy statement and annual report, go to www.proxydocs.com/NVUS. To submit your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. We have chosen to use these procedures for our 2020 Annual Meeting and need YOUR participation.

If you want to receive a paper or e-mail copy of the proxy materials, you must request one by following the instructions below. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's annual meeting, please make this request on or before April 27, 2020. You may also request paper or e-mail copies of the proxy materials for all future meetings.

For a Convenient Way to VIEW Proxy Materials – and – VOTE Online go to: www.proxydocs.com/NVUS

Proxy Materials Available to View or Receive:
1. Proxy Statement 2. Annual Report

Printed or emailed materials may be requested by one of the following methods:


INTERNET
www.investorelections.com/NVUS


TELEPHONE
(866) 648-8133


***E-MAIL**
paper@investorelections.com

You must use the 12 digit control number located in the shaded gray box below.

* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions or other inquiries should be included with your e-mail requesting material.

ACCOUNT NO.

SHARES

Company Notice of Annual Meeting

Date: May 12, 2020
Time: 11:30 A.M. PDT
Place: Novus Therapeutics, Inc. 19900 MacArthur Boulevard,
Suite 550 Irvine, CA 92612

The purpose of the Annual Meeting is to take action on the following proposals:

The Board of Directors recommends that you vote "FOR" the following.

1. Election of Directors
Nominees 01 Gregory J. Flesher 02 Gary A. Lyons

The Board of Directors recommends that you vote "FOR" the following, and "3 YEARS" on proposal 5.

- Ratification of the appointment of KMJ Corbin & Company LLP as our Independent registered public accounting firm for the fiscal year ending December 31, 2020.
- To approve and adopt an amendment to our Certificate of Incorporation to effect a reverse stock split of our common stock, at a ratio ranging from 1 share for 10 shares to 1 share for 30 shares, as determined by our board of directors.
- Advisory (non-binding) vote to approve the compensation of our named executive officers.
- Advisory (non-binding) vote on the frequency of future advisory votes to approve executive compensation.

Vote In-Person Instructions: While we encourage stockholders to vote by the means indicated above, a stockholder is entitled to vote in person at our 2020 Annual Meeting. In order to attend the meeting and vote in-person, you will need to bring photo identification and proof of ownership as of the record date, March 16, 2020.